Brief: Ironwood Pharmaceuticals Presents Positive Final Data From Stars Nutrition, A Phase II Study Of Apraglutide In Short Bowel Syndrome With Intestinal Failure And Colon In Continuity At United European Gastroenterology Week
16/10/2023 11:47
Oct 16 (Reuters) - Ironwood Pharmaceuticals Inc
IRWD.O :
* IRONWOOD PHARMACEUTICALS PRESENTS POSITIVE FINAL DATA FROM
STARS
NUTRITION, A PHASE II STUDY OF APRAGLUTIDE IN SHORT BOWEL
SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON IN
CONTINUITY (CIC) AT UNITED EUROPEAN GASTROENTEROLOGY WEEK
* IRONWOOD PHARMACEUTICALS INC - DATA SHOW APPROXIMATELY 50%
REDUCTION OF PARENTERAL SUPPORT (PS) VOLUME
* IRONWOOD PHARMACEUTICALS INC - APRAGLUTIDE WAS WELL
TOLERATED
WITH AN ACCEPTABLE SAFETY PROFILE
Source text for Eikon: ID:nBw2Dn7l5a
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation